Advanced Therapies – Challenges for Routine Applications

17. - 18. Mai 2022
DECHEMA-Haus, Frankfurt am Main

In recent years, Advanced Therapy Medicinal Products (ATMP) have evolved into a promising and highly hoped-for medical approach to cure a broad spectrum of inherited and acquired human diseases, ranging from cancer to immunological disorders and rare diseases. However, the path from development to clinical application is not yet routine.

The conference will highlight the challenging field of gene and cell therapeutics.

Advances in development and manufacturing will be presented at ATMP 2022, as well as quality control methods and regulatory aspects: The focus is on the path to safe and beneficial advanced therapies for the patient.

The registration is open: Register now!


Keynote Speakers

Conference Topics


The challenges and issues of manufacturing and analytics of gene and cell therapeutics are very different from all other therapeutics, including biopharmaceuticals. A key factor of success is the management of multiple challenges addressing safety, purity and potency of these advanced therapies.

Robust and reliable manufacturing processes are still far from routine. Efficient gene transfer vectors, delivering the therapeutic gene into the target cells without causing any associated pathogenic effect, need to be developed and produced in large-scale.
Depending on the complexity and individuality of this product class, cell therapy manufacturing processes may comprise consistent procedures of culture, expansion, genetic manipulation, stimulation, and in case of treatments of multiple patients, cell banking. Analytics and quality control need to be adapted to this broad range of complex manufacturing processes ensuring adequate safety, purity and potency of the final products.

The conference is an initiative of the DECHEMA working groups
Cell Culture Technology and Medical Biotechnology.


Jetzt Mitglied werden